FOXO Technologies Inc. Regains NYSE American Compliance with Stockholders’ Equity Exceeding $4 Million

FOXO Technologies Inc. (NYSE American: FOXO) recently announced in a press release dated December 16, 2024, that the company has successfully met the stockholders equity requirement exceeding $4 million. This achievement ensures compliance with the NYSE American continued listing standards.

In efforts to address a prior stockholders’ deficit outlined in the Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on November 19, 2024, FOXO engaged in various strategic transactions. Notable among these transactions were agreements with Rennova Health, Inc., an institutional investor, and KR8 AI, Inc., alongside conversions of liabilities and notes into equity.

According to Seamus Lagan, the Chief Executive Officer of FOXO, the surpassing of the $4 million stockholders’ equity milestone eliminates the risk of delisting from the NYSE American exchange. Lagan emphasized the company’s commitment to growth and enhancement, ensuring continued benefits for its shareholders in the future.

A detailed account of these transactions and related company initiatives was provided in a Current Report on Form 8-K filed with the SEC on December 10, 2024. This report offers additional insights into FOXO’s recent actions and future plans to address stockholders’ equity requirements for NYSE American listing.

FOXO Technologies Inc., a company consisting of three subsidiaries including Foxo Labs, Inc., Myrtle Recovery Centers, Inc., and Rennova Community Health, Inc., remains dedicated to enhancing human health and lifespan through cutting-edge technology solutions across various sectors.

Cautionary language regarding forward-looking statements was emphasized by FOXO, indicating that while the recent achievements reflect positive momentum, uncertainties and risks still persist, potentially impacting future results. FOXO has reassured investors of its commitment to regulatory compliance and continuous update of stakeholders as events progress.

For further details on FOXO Technologies Inc., visit www.foxotechnologies.com.

Contact:
Crescendo Communications, LLC
Phone: (212) 671-1020
Email: [email protected]

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read FOXO Technologies’s 8K filing here.

FOXO Technologies Company Profile

FOXO Technologies Inc engages in epigenetic biomarker underwriting technology and consumer engagement platform service business in the United States. It operates through two segments, FOXO Labs and FOXO Life. The company applies automated machine learning and artificial intelligence technologies to discover epigenetic biomarkers of human health, wellness, and aging.